Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

11/12/24 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $GLYC alert in real time by email

Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors

WALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT.

A live webcast of the presentation will be available at https://wsw.com/webcast/jeff315/cresc/1987776. An archived recording will be available for 90 days following the event.

In late October, Crescent entered into an acquisition agreement with Rockville, Maryland-based GlycoMimetics, Inc. (NASDAQ:GLYC). Following closing, the combined company will operate under the name Crescent and advance its portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors.

About Crescent Biopharma

Crescent Biopharma is a biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors. The company's pipeline of three programs harnesses proven biology to accelerate the path to market for potentially best-in-class therapeutics. For more information, visit www.crescentbiopharma.com.

Media Contact:

Deerfield Group

Lia Dangelico

540-303-0180

[email protected]

Investor Contact:

Argot Partners

Dawn Schottlandt

212-600-1902

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/crescent-biopharma-to-present-at-jefferies-london-healthcare-conference-2024-302301827.html

SOURCE Crescent Biopharma

Get the next $GLYC alert in real time by email

Date

Price Target

Rating

Analyst

7/26/2024

Buy → Hold

TD Cowen

12/22/2023

$12.00

Overweight

CapitalOne

11/12/2021

$3.00 → $4.00

Hold → Buy

Jefferies

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Chat with this insight

Recent Analyst Ratings for $GLYC

$GLYC Press Releases

Fastest customizable press release news feed in the world

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

$GLYC SEC Filings

SEC Form 10-Q filed by GlycoMimetics Inc.

SEC Form DEFA14A filed by GlycoMimetics Inc.

GlycoMimetics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$GLYC Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Rock Edwin bought $78,824 worth of shares (305,000 units at $0.26), increasing direct ownership by 81% to 680,403 units (SEC Form 4)

SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), increasing direct ownership by 33% to 70,643 units (SEC Form 4)

SEC Form 4: Rock Edwin bought $90,256 worth of shares (65,403 units at $1.38), increasing direct ownership by 21% to 375,403 units

$GLYC Large Ownership Changes

This live feed shows all institutional transactions in real time.

$GLYC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$GLYC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Amendment: SEC Form SC 13G/A filed by GlycoMimetics Inc.

SEC Form SC 13G filed by GlycoMimetics Inc.

SEC Form SC 13D filed by GlycoMimetics Inc.

Large owner Invus Public Equities, L.P. sold $61,206 worth of shares (322,361 units at $0.19) (SEC Form 4)

Large owner Invus Public Equities, L.P. sold $41,184 worth of shares (220,255 units at $0.19) (SEC Form 4)

Large owner Invus Public Equities, L.P. sold $71,097 worth of shares (349,764 units at $0.20) (SEC Form 4)

GlycoMimetics downgraded by TD Cowen

CapitalOne initiated coverage on GlycoMimetics with a new price target

GlycoMimetics upgraded by Jefferies with a new price target

$GLYC Market Insights

Live Market Insights

On June 21, GlycoMimetics Got Notice From Nasdaq, Co Is Not In Compliance With Nasdaq's Listing Rule 5450(a)(1)

Why GlycoMimetics Stock is Trading Higher Monday

$GLYC Insider purchases explained

Analytical look into recent insider purchases

What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

$GLYC Financials

Live finance-specific insights

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

$GLYC Leadership Updates

Live Leadership Updates

GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer

GlycoMimetics Appoints Deepak Tiwari, Ph.D., as new Vice President, Technical Operations

GlycoMimetics Appoints Bruce Johnson Senior Vice President and Chief Commercial Officer

Recent Analyst Ratings for
$GLYC

$GLYC
Press Releases

$GLYC
SEC Filings

$GLYC
Insider Purchases

$GLYC
Large Ownership Changes

$GLYC
Insider Trading

$GLYC
Analyst Ratings

$GLYC
Market Insights

$GLYC
Insider purchases explained

$GLYC
Financials

$GLYC
Leadership Updates